EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia

Michele H Potashman, Evan Popoff, Lauren C Powell, Melissa Wolfe Beiner, Ainsley Mackenzie, Vlad Coric, Sub Subramony, Matthis Synofzik, Jeremy Schmahmann, Gilbert L'Italien

Neurology and Therapy · 2025-04 · 14 (2) · 527-545

DOI: 10.1007/s40120-024-00708-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 13.01.2025. Verfasst von Michele H Potashman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biohaven Pharmaceuticals, Inc, 215 Church Street, New Haven, CT, 06510, USA. Michele.potashman@biohavenpharma.com. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Biohaven Pharmaceuticals, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL) is a valid, highly utilized measure for assessing ADL impacts in patients with Friedreich ataxia. We provide evidence of the psychometric validity of the FARS-ADL in two cohorts of patients with spinocerebellar ataxia (SCA). METHODS: Using data from a cohort of real-world subjects with SCA (recruited at Massachusetts General Hospital [MGH]; n = 33) and a phase 3 trial of troriluzole in adults with SCA (NCT03701399 [Study 206]; n = 217), comprising a subset of patients with the SCA3 genotype (n = 89), the psychometric measurement properties and minimal change thresholds of the FARS-ADL were examined. RESULTS: Ceiling effects for the FARS-ADL were absent within the MGH cohort while floor effects were observed for eight of nine items. Excellent internal consistency reliability was observed (αtotal = 0.88; αitems-removed = 0.86-0.87), and item-to-total correlations were acceptable (r = 0.55-0.89 per item). Convergent and divergent validity were supported with strong correlations demonstrated between FARS-ADL and scales measuring similar concepts (Neuro-QOL [Upper], Neuro-QOL [Lower], PROM-ADL, PROM-PHYS, and FARS-FUNC; all P < 0.001) and weaker correlations shown between measures of differing constructs. A two- to three-point threshold for meaningful changes was supported as 0.5 × SD = 2.43, SEM = 2.19. Mean changes from baseline for subjects classified as "improved," "no change," or "deteriorated" were -0.54, 0.22, and 1.47, respectively. Similar trends were observed in the Study 206 all-SCA and SCA3 cohorts. CONCLUSION: Psychometric evaluation showed that the FARS-ADL performed well on analyses examining the reliability and validity of the measure and can detect meaningful changes in patients with SCA, including those with SCA3. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03701399 (Study 206).

Schlagwörter

Stichwörter der Autor:innen

Activities of daily livingOutcomes assessmentPsychometricsSpinocerebellar ataxiasValidation study

Autor:innen und Institutionen

  • Biohaven Pharmaceuticals, Inc, 215 Church Street, New Haven, CT, 06510, USA. Michele.potashman@biohavenpharma.com.
  • Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada.
  • Biohaven Pharmaceuticals, Inc, 215 Church Street, New Haven, CT, 06510, USA.
  • Department of Neurology, University of Florida College of Medicine, Gainesville, FL, USA.
  • Division of Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University Tübingen, Tübingen, Germany.
  • Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Förderung

  • Biohaven Pharmaceuticals, Inc

Zitieren

APA

Potashman, M. H., Popoff, E., Powell, L. C., Beiner, M. W., Mackenzie, A., Coric, V., Subramony, S., Synofzik, M., Schmahmann, J., & L'Italien, G. (2025). Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia. Neurology and Therapy, 14(2), 527-545. https://doi.org/10.1007/s40120-024-00708-4

Vancouver

Potashman MH, Popoff E, Powell LC, Beiner MW, Mackenzie A, Coric V, et al. Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia. Neurology and Therapy. 2025;14(2):527-545. doi:10.1007/s40120-024-00708-4

BibTeX
@article{Potashman2025,
  author = {Potashman, Michele H and Popoff, Evan and Powell, Lauren C and Beiner, Melissa Wolfe and Mackenzie, Ainsley and Coric, Vlad and Subramony, Sub and Synofzik, Matthis and Schmahmann, Jeremy and L'Italien, Gilbert},
  title = {Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia},
  journal = {Neurology and Therapy},
  year = {2025},
  volume = {14},
  number = {2},
  pages = {527--545},
  doi = {10.1007/s40120-024-00708-4}
}
Kostenlos starten →